AZTA

Azenta, Inc. (AZTA) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended December 31, 2025 (Fiscal Q1 2026). Azenta, Inc. is a global provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The company operates through two primary continuing segments: Sample Management Solutions and Multiomics. The reporting period is significantly impacted by the classification of the B Medical Systems business as "discontinued operations" following a definitive agreement to sell the unit.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 0.8% year-over-year, driven by a 1.4% increase in the Multiomics segment, while Sample Management Solutions remained flat.
• Margin Compression: Gross margin declined 380 basis points to 42.9%. This was primarily due to lost cost leverage in Sanger Sequencing (Multiomics) and higher rework costs on Automated Stores projects (Sample Management Solutions).
• Operating Expenses: Total operating expenses decreased $6.6 million, largely due to reduced Selling, General, and Administrative (SG&A) expenses, partially offset by a $2.1 million increase in R&D spending.
• Discontinued Operations Impact: The net loss from discontinued operations increased significantly to $10.2 million (from $3.9 million) due to a $9.7 million loss on assets held for sale related to the pending divestiture of B Medical Systems.
• Accounting Revisions: The company revised prior period financial statements (Q1 2025) to correct misclassifications between cost of revenue and operating expenses. The reported Q1 2025 figures in this summary reflect these revisions.

Guidance, Outlook, and Risks

• Divestiture of B Medical Systems: Azenta entered a definitive agreement to sell B Medical Systems for $63.0 million. A $9.0 million deposit has been received, with the remaining $54.0 million contingent on the buyer securing financing by March 31, 2026. Failure to close could result in the business remaining in continuing operations and potential additional impairment charges.
• Share Repurchase Program: The Board approved a new $250 million share repurchase program effective December 8, 2025, running through December 31, 2028. No shares have been repurchased under this new program to date.
• Internal Control Weaknesses: The company disclosed that disclosure controls and procedures were not effective as of December 31, 2025, due to material weaknesses in cash flow statement review, account reconciliations, and expense classification. Remediation plans are underway but not yet fully effective.
• Legal Contingencies: An ongoing dispute regarding the 2019 sale of the semiconductor cryogenics business to Edwards Vacuum LLC remains, with an accrued liability of $2.1 million.
• Outlook: Management expects to complete restructuring initiatives by the end of fiscal 2026. The company anticipates continued investment in R&D to support new product introductions.

Investor Verification Checklist

• Divestiture Closing Risk: Verify the status of Thelema's financing for the B Medical Systems sale, as the transaction is not yet closed and carries a break-up fee risk.
• Internal Control Remediation: Monitor progress on remediation of material weaknesses in internal controls over financial reporting, specifically regarding cash flow statements and expense classification.
• Margin Recovery: Assess whether the margin compression in Multiomics (Sanger Sequencing volume) and Sample Management (rework costs) is a temporary issue or indicative of structural cost pressures.
• Discontinued Operations: Confirm that the $9.7 million loss on assets held for sale is fully accounted for and that no further impairments are expected if the sale delays.
• Capital Allocation: Track execution of the new $250 million share repurchase program and its impact on liquidity and earnings per share.